Food/Recall·openFDA/food

L-Nutra Inc — Class II: Prolon Everyday Apulian Almond & Cocoa Spread, NET WT: 8.47 OZ. Product packaged in glass

MediumPublished Sep 16, 2026· AI-analyzed Sep 22, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

L-Nutra Inc has initiated a Class II recall for its Prolon Everyday Apulian Almond & Cocoa Spread due to undeclared tree nut allergens, specifically hazelnut, cashew, and pistachio. The product was distributed in 8.47 oz glass jars with UPC 50040360530.

Who it affects

L-Nutra Inc, quality assurance teams, labeling compliance officers, and downstream distributors or retailers handling the affected almond and cocoa spread.

Why it matters

The presence of three undeclared allergens (hazelnut, cashew, pistachio) suggests a potential breakdown in allergen cross-contact controls or a significant labeling oversight. A Class II designation indicates that exposure to the product may cause temporary or medically reversible adverse health consequences. Regulatory teams should consider this an indicator to verify that multi-nut processing environments have robust segregated cleaning protocols and accurate label-verification systems.

Practical takeaway

Conduct an immediate reconciliation of raw material specifications against final product labels for this SKU. Review allergen control plans and verification procedures at the manufacturing site to identify how three distinct tree nuts (hazelnut, cashew, pistachio) were omitted from the ingredient declaration.

FDA source material

Class II. Reason: Undeclared allergen (tree nuts): hazelnut, cashew, and pistachio.. Product: Prolon Everyday Apulian Almond & Cocoa Spread, NET WT: 8.47 OZ. Product packaged in glass jar with white label and gold screw on closure. UPC: 50040360530. Firm: L-Nutra Inc (Los Angeles CA United States). Status: Ongoing.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.